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Abstract 
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein expressed in the astrocyte 
cytoskeleton that plays an important role in the structure and function of the cell. GFAP can be 
phosphorylated at six serine (Ser) or threonine (Thr) residues but little is known about the role of 
GFAP phosphorylation in physiological and pathophysiological states. We have generated 
antibodies against two phosphorylated GFAP (pGFAP) proteins: p8GFAP, where GFAP is 
phosphorylated at Ser-8 and p13GFAP, where GFAP is phosphorylated at Ser-13. We examined 
p8GFAP and p13GFAP expression in the control neonatal pig brain and at 24h and 72h after an 
hypoxic-ischemic (HI) insult. Immunohistochemistry demonstrated pGFAP expression in astrocytes 
with an atypical cytoskeletal morphology, even in control brains. Semi-quantitative western blotting 
revealed that p8GFAP expression was significantly increased at 24h post-insult in HI animals with 
seizures in frontal, parietal, temporal and occipital cortices. At 72h post-insult, p8GFAP and 
p13GFAP expression were significantly increased in HI animals with seizures in brain regions that 
are vulnerable to cellular damage (cortex and basal ganglia), but no changes were observed in brain 
regions that are relatively spared following an HI insult (brain stem and cerebellum). Increased 
pGFAP expression was associated with poor neurological outcomes such as abnormal 
encephalography (EEG) and neurobehaviour, and increased histological brain damage. 
Phosphorylation of GFAP may play an important role in astrocyte remodelling during development 
and disease and could potentially contribute to the plasticity of the central nervous system. 
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Introduction 
Astrocytes are the key supporting cells in the brain and their function is critical for normal brain 
activity. Astrocytes provide the link between blood vessels and neurons, and regulate molecules 
such as neurotransmitters, energy sources, water and ions. Glial fibrillary acidic protein (GFAP) is a 
type III intermediate filament protein expressed by subsets of grey and white matter astrocytes 
throughout the central nervous system (CNS) [1]. GFAP knockout mice are more susceptible to 
brain damage caused by trauma or ischemia than wild-type mice [2-4]. 63% of astrocytes from 
GFAP knockout mice have altered morphology (short, less branched processes) compared with wild 
type astrocytes [2]. GFAP is undoubtedly an important protein: 76 GFAP gene mutations have been 
associated with the rare but fatal neurodegenerative condition Alexander disease [5]. Changes in 
GFAP mRNA or protein expression have been associated with diseases such as Alzheimer’s 
disease, Creutzfeldt-Jacob disease, Downs Syndrome, stroke, traumatic brain injury, and 
amyotrophic lateral sclerosis [1,5]. Like other intermediate filament proteins, GFAP plays an 
important role in determining the shape of the cell and can also influence glutamate homeostasis: 
Our previous studies have shown that GFAP (via NHERF1 and ezrin) anchors the glutamate 
transporter GLAST in the plasma membrane, enhancing glutamate transport [6].  
 
GFAP can be phosphorylated at multiple sites, including Thr-7, Ser-8, Ser-13, Ser-17, Ser-34/38 
and Ser-389. These six amino acid residues are highly conserved among species, implying the 
biological importance of GFAP phosphorylation [7]. Enzymes including protein kinase A (PKA), 
protein kinase C (PKC), calcium/calmodulin dependent protein kinase II (CaMKII), Rho kinase, 
cleavage furrow (CF) kinase and Cdc2 kinase modulate the phosphorylation of one or more of the 
GFAP residues [8-12]. Phosphorylation in the N-terminal region (head domain) affects GFAP 
assembly and in the C-terminal region (tail domain), phosphorylation of Ser-389 affects interactions 
between GFAP and other intermediate filaments or proteins [10]. Phosphorylation of GFAP causes 
disassembly of the intermediate filaments and conversely, dephosphorylation (by phosphatase) 
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restores its ability to polymerize [8]. Various knock-in mice have been created that replace three to 
five of the six GFAP phosphorylation sites with an alanine residue [7]. When five Ser/Thr residues 
in the head domain were replaced with alanine residues, there was a significant decrease in GFAP 
immunoreactivity in most brain regions and the filamentous structures of GFAP were lost in long 
processes. When Ser-13, Ser-17 and Ser-38 were replaced, there was a slight decrease in GFAP 
immunoreactivity and labelling was associated with astrocytes with short processes [7]. The 
integrity of the cytoskeleton is essential for normal astrocyte function, thus GFAP phosphorylation 
may be an important regulatory mechanism in CNS plasticity during development or in disease 
conditions.  
 
Hypoxia-ischemia (HI, reduced oxygen availability and/or blood supply) commonly occurs during 
parturition. HI triggers a cascade of biochemical and molecular events that initially involve 
decreased energy, glucose and pH, ionic imbalance and glutamate release [13]. After reperfusion, 
oxygen levels may be restored but the brain remains vulnerable to further injury that can be 
perpetuated by multiple biological pathways, commonly referred to as secondary energy failure 
[14]. Neuronal and glial cells die as a result of one or more cell death pathways, for example, 
excitotoxicity, oxidative stress, cellular oedema and inflammation [15]. This brain damage develops 
over a period of days to weeks; therefore, a therapeutic window exists for treatment or intervention 
[16].  
 
In response to CNS insult or injury, astrocytes commonly undergo reactive gliosis, upregulating 
GFAP and infiltrating areas where neurons are damaged, creating a glial scar [17]. There is 
increasing evidence that reactive gliosis and glial scar formation are beneficial for the repair of the 
injured brain [18-20]. The glial scar borders severely damaged tissue, creating a barrier against 
inflammatory cells and neurotoxic agents and facilitating recovery processes such as blood-brain 
barrier repair and stabilizing the balance of ions and neurotransmitters in the extracellular space. 
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Astrocytes play an important role in the ischemic brain [21] but we believe that the gliosis 
described in rodent studies (for example [22]) occurs at a later time point in the pig HI model. This 
theory is supported by Martin et al. [23] who demonstrated a significant increase in GFAP 
immunoreactivity in the HI pig brain at 96h post-insult. Our previous studies have demonstrated 
that the post-HI brain undergoes significant changes in the expression of various astrocytic and 
neuronal proteins and the structure of grey and white matter astrocytes [6,24-29]. We have 
demonstrated pre-gliotic astrocyte changes are evident from 1-8h after an HI insult, prior to 
histological evidence of neuronal damage [6,29]. At 72h post-insult, overall astrocyte size 
decreased by 30-40% in grey and white matter and these astrocytic changes were associated with 
histological brain damage [6,28]. Our results and others confirm the importance of neuron-glia 
interactions in normal brain function [30]. 
 
The post-HI brain is vulnerable to excitotoxicity due to the loss of the glutamate transporters 
GLAST and GLT-1, which would lead to an accumulation of glutamate in the synapse [24]. High 
levels of extracellular glutamate and intracellular calcium stimulate phosphorylation of GFAP [31]. 
Our piglet HI model is ideal for investigating GFAP phosphorylation as some animals develop post-
HI seizures, which would further increase levels of glutamate in the extracellular space. In this 
study, we have investigated whether GFAP phosphorylation is altered after HI insults. We studied 
the expression of two phosphorylated GFAP (pGFAP) proteins, p8GFAP and p13GFAP, where 
GFAP is phosphorylated at Ser-8 and Ser-13, respectively. We have used a clinically-relevant 
animal model: The neonatal pig model of HI produces similar outcomes to human HI infants in 
terms of the regions of the brain that are damaged (cortex and hippocampus) and the presentation of 
seizures in some individuals. High levels of extracellular glutamate and intracellular calcium 
stimulate GFAP phosphorylation, and since both of these occur in the cascade of events after an HI 
insult, we hypothesised that there would be increased levels of pGFAP in HI brains. 
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Materials and methods 
All studies were approved by the University of Queensland Animal Ethics Committee and 
experiments were carried out in accordance with NHMRC (Australia) guidelines. Adequate 
measures were taken to minimise pain or discomfort to animals. 
 
Generation of antibodies 
Polyclonal antibodies were generated in New Zealand White rabbits and Sprague Dawley rats 
against p8GFAP, p13GFAP and the non-phosphorylated form of GFAP, using protocols previously 
described [32]. Amino acids 3-13 of human GFAP (GenBank #P14136) were selected to create 
antibodies against, as Ser-8 and Ser-13 are known phosphorylation sites [31]. The unique peptides 
RRRITpSAARRS for p8GFAP, RRRITSAARRpS for p13GFAP and RRRITSAARRS for the non-
phosphorylated form of GFAP were synthesised by GL Biochem (Shanghai, China). As per 
previously published methods [33,34], dot blots were initially performed to assess the specificity of 
the antibodies. Further characterisation of the antibodies was performed using western blotting, as 
detailed below. 
 
Animals 
Forty-six newborn Large White pigs were obtained from The University of Queensland Gatton 
piggery. In the 24h group (N=23), there were seven controls and 16 HI animals, of which seven 
developed post-HI seizures. In the 72h group (N=23), there were six controls and 17 HI animals, of 
which eight developed post-HI seizures. To eliminate any confounding effects of anticonvulsant 
drugs, animals that developed seizures were not treated in this study. 
 
Animal Experiments 
Animals were anaesthetised, ventilated and physiological variables monitored as previously 
described [35,36]. In brief, pigs were rendered hypoxic by decreasing the inspired oxygen (iO2) to 
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4% for 30min. Hypotension (ischemia) was induced for the final 10min of the insult by reducing 
iO2 until the mean arterial blood pressure (MABP) was <70% of the baseline (~30mm Hg). 
Littermate controls (N=13) underwent anaesthesia only. Electroencephalography (EEG) was 
recorded (BRM2; BrainZ Instruments, Auckland, NZ) each day post-insult and neurobehavioural 
scoring was performed at 8h, 12h, 16h, 24h, 48h and 72h post-insult. Nine behavioural items were 
assessed as normal (2), moderately abnormal (1), or definitely pathologic (0), with a maximum 
score of 18 representing normal neurobehaviour. 
 
Animals were euthanased at 24h or 72h post-insult by an overdose of sodium pentobarbital 
(Lethabarb, 100 mg/kg, I.P.). Brains were removed and 3mm-thick coronal slices prepared. Slices 
from the right hemisphere were fixed by immersion for 16h in 4% paraformaldehyde in 0.1M 
phosphate buffer (pH 7.2). Slices from the left hemisphere were further dissected into regions of 
interest (frontal, parietal, temporal and occipital cortices, basal ganglia, thalamus, hippocampus, 
brain stem and cerebellum) and frozen in 0.32M sucrose. 
 
Histology 
Brain slices were dehydrated, cleared in xylene and embedded in paraffin wax. Tissue sections 
(4µm) were cut on a rotary microtome and stained with haematoxylin and eosin to assess cellular 
brain damage. Sections were graded 0-10 based on the highest level of damage observed in a region 
and the percentage area this lesion occupied (Table 1). Two non-adjacent sections from each region 
(frontal, parietal, temporal and occipital cortices, basal ganglia, hippocampus, thalamus and 
cerebellum) were scored by blinded observers (ZI and SS). Sections from the same animal were 
scored non-sequentially to avoid bias and the average was taken from these scores. The total 
histology score was represented as a scaled average, with 100 indicating that all regions examined 
scored the most severe grade of 10.  
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Western blotting 
Protein samples were created by homogenizing the tissue in a 10x volume of ice-cold ddH2O. 
Samples were spun at 1,400 x g at 4°C and the supernatant retained. Protein concentrations were 
estimated by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Scoresby, Australia). Brain 
homogenates were subjected to 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
then transferred to PVDF membrane. For quantification studies, a protein standard was included on 
every gel to control for inter-assay variability. The standard was created by pooling 100µL of 
protein sample made from each brain region from all pigs studied. Membranes were blocked for 1h 
in 1% skim milk powder in tris-buffered saline-Tween (TBST; 137mM NaCl, 2.7mM KCl, 19mM 
Tris, 0.1% Tween-20) with agitation and incubated overnight at 4°C with the primary antibody 
diluted 1:15,000 (p8GFAP and p13GFAP). The membranes were washed in TBST and the anti-
rabbit secondary antibody IgG-peroxidase conjugate (Sigma, Castle Hill, Australia) was diluted 
1:30,000 in 1% skim milk powder in TBST, added to the membranes and incubated for 1h. The 
membranes were washed, ECL+ reagent (GE Healthcare, Sydney, Australia) was applied to the 
membranes and the blots exposed to X-ray film and developed. Membranes were incubated for 1h 
in stripping buffer (0.2M glycine, 3.47mM SDS, 1% Tween-20, pH 2.2) at 55°C with gentle 
agitation and then rinsed in TBST, ECL+ applied and re-exposed to film to ensure antibodies were 
effectively removed. Immunoblotting was performed as above for GFAP using the primary 
antibody at 1:400,000 (Rabbit anti-GFAP; DakoCytomation, Glostrup, Denmark). 
 
Specificity of the p8GFAP and p13GFAP antibodies was tested using western blotting. In this 
instance, the primary antibody solution was replaced by a pre-absorbed primary antibody solution. 
This solution was created using a BSA conjugate supplemented with 0.2M glycine (50µL per 
1.1mL of conjugate). 500µL of conjugate was added per 10mL of blocking solution and the primary 
antibody was diluted at 1:15,000. The pre-absorbed solution was incubated overnight at 4°C with 
agitation before using on the membrane. 
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Western blotting and dephosphorylation treatment were used to further examine the specificity of 
the p8GFAP and p13GFAP antibodies. Protein homogenates were electrophoresed, transferred to 
PVDF membrane and blocked in 1% skim milk powder in TBST. The membrane to be 
dephosphorylated was placed in buffer (100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, 1mM 
dithiothreitol) with 2mL of 5mg/mL alkaline phosphatase (Sigma, Castle Hill, Australia) and 
incubated for 16h at 37°C with gentle agitation. Western blotting, detection of pGFAP, stripping of 
membranes and detection of GFAP was performed as above. 
 
Immunohistochemistry 
Tissue slices for pGFAP immunohistochemistry were further fixed in 4% paraformaldehyde 
supplemented with 0.25% glutaraldehyde for 3h. Tissues were embedded in warm 4% agarose and 
50µm-thick sections were cut with a vibrating microtome. Sections were incubated in 3% H2O2 to 
in 0.1M sodium phosphate buffer (PBS, pH 7.2) to inhibit endogenous peroxidases and then 
blocked in 0.5% BSA/0.05% saponin/0.05% sodium azide in PBS for 30min. 
Immunohistochemistry for pGFAP was performed using the p8GFAP or p13GFAP rat or rabbit 
polyclonal antibodies diluted at 1:2,500. GFAP immunohistochemistry was performed using a 
rabbit polyclonal antibody (DakoCytomation, Glostrup, Denmark) at 1:5,000. Biotinylated or Texas 
Red-conjugated species-specific secondary antibodies were utilized followed by Streptavidin-FITC 
for fluorescence visualisation or streptavidin-HRP complex (all reagents from GE Healthcare, 
Australia) for immunoperoxidase visualisation. Immunoperoxidase labelling was revealed using 
DAB as a chromagen. Sections for immunofluorescence were stained with the fluorescent dye 4,6-
diamidinno-2-phenylidole (DAPI; Sigma, Australia) to selectively label the nuclei of the cells. 
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Amplitude-integrated EEG (aEEG) scoring system 
Five distinct background aEEG patterns have been described in neonatal humans and pigs: 
Continuous normal voltage (CNV), discontinuous normal voltage (DNV), burst suppression (BS), 
continuous low voltage (CLV) and flat trace (FT) [37,38].  For analysis, the aEEG recordings were 
reviewed (by SMM) in Analyze version 1.5 software (BrainZ Instruments Ltd, New Zealand) and 
scored as per Table 2. The scoring system ranges from 0-5.5, with 0 representing normal aEEG and 
5.5 being severely abnormal aEEG. Seizures were defined electrographically as repetitive, rhythmic 
waveforms (duration >10sec) with distinct beginning and end, and clinically as myoclonic jerks, 
rhythmic pathologic movements (cycling) or tonic postures.  
 
Data collection, analysis and statistics 
Imaging was performed using a Zeiss Axio Imager Z1 microscope with a Zeiss AxioCam MRm 
Rev.3 or AxioCam HRc digital camera. Composite plates of the TIFF images were generated using 
Adobe Illustrator CS4. Graphs were created in Prism 5.0c for Mac OS X. Data was analysed using 
IBM SPSS Statistics v19. Shapiro-Wilk test for normality of data was performed. One-way analysis 
of variance (ANOVA) with Games-Howell post hoc analysis was used to assess differences 
between the means of more than two groups if data were normally distributed. Sex differences were 
examined using a Student’s t-test. Non-parametric analyses were employed for data that was non-
normally distributed (Spearman correlation or Kruskal-Wallis test with Mann-Whitney U post-hoc 
analysis). Differences were considered significant if the p-value was less than 0.05. 
 
Results 
Characterisation of antibodies 
Dot blots confirmed that the p8GFAP and p13GFAP antibodies specifically recognised the GFAP 
peptide when Ser-8 or Ser-13 was phosphorylated but did not cross-react with each other or 
recognise the same GFAP peptide sequence without phosphorylation (data not shown). Western 
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blotting was performed with normal and pre-absorbed p8GFAP or p13GFAP primary antibody 
solutions to confirm that the 50kDa band detected was specific to p8GFAP or p13GFAP. No band 
was detected if the primary antibody was omitted or the pre-absorbed solutions were used (Fig. 1). 
Further western blotting experiments were performed to determine that the pGFAP antibodies were 
indeed detecting a phosphoprotein (Fig. 2). The p8GFAP antibody failed to detect p8GFAP if the 
membranes were dephosphorylated. Immunoblotting for GFAP revealed that regular GFAP was 
detected in both the normal membrane and the dephosphorylated membrane (Fig. 2C). The 
p13GFAP antibody showed a similar result (data not shown). 
 
Group variables 
To determine whether animals developed seizures due to having a more severe HI insult, we 
examined the insult variables across the six groups – controls, HI and HI animals with seizures 
(here after referred to as HI-seizure animals) at the two time points (Table 3). All HI animals (four 
groups) received a similar insult, that is, no significant differences were observed between HI and 
HI-seizure animals for any variables at their respective time points. As expected, at both time points 
control animals were statistically different (p<0.01) to both the HI and HI-seizure animals in terms 
of the insult variables. Animals at each time point received a similar insult: No significant 
differences were detected between the 24h and 72h control, HI or HI-seizure animals. There were 
no significant sex differences observed for any variables (data not shown).  
 
Cellular localisation of pGFAP 
Double immunolabelling was performed to confirm that pGFAP was expressed in astrocytes in the 
control brain (Fig. 3). The p13GFAP antibody detected a protein specifically expressed in 
astrocytes (Fig. 3A), which co-localised with GFAP detected using a commercial antibody (Fig. 
3B-C). GFAP and pGFAP were differentially expressed in the astrocyte. Expression of pGFAP was 
concentrated in processes near the cell body, but also expressed in unusual terminal dilations of the 
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astrocyte processes (arrowhead, Fig. 3D) and parts of the astrocyte process in between (double 
arrowhead, Fig. 3D). pGFAP expression was also observed in end-feet of astrocytes contacting 
blood vessels (Fig. 3E). Similar results were observed using the p8GFAP antibody (data not 
shown). 
 
Expression of pGFAP in control and HI brains with mild or no cellular damage was similar (Fig. 
4A-B). Astrocytes expressing pGFAP had abnormal cytoskeletal morphology (Fig. 4). The majority 
of labeled astrocytes had very short processes. The few astrocytes that expressed pGFAP in long 
processes had atypical features such as thickened, varicose processes (Fig. 4D) and did not exhibit 
the fine, bushy processes of a normal control astrocyte (see images contained within [6,39]). 
Immunolabelling for pGFAP in HI brains with moderate to severe cellular damage (72h post-insult) 
revealed that pGFAP expression was upregulated (Fig. 4C). In these animals, astrocytes had 
abnormal cytoskeletal morphology with shortened cell processes (Fig. 4E). 
 
pGFAP in brain homogenates 
Semi-quantitative western blotting was performed to examine p8GFAP and p13GFAP expression in 
nine brain regions from control, HI and HI-seizure animals at 24h and 72h post-insult. Figure 5 
shows an example western blot result from three representative animals at 72h post-insult. 
Expression of p8GFAP was upregulated in HI-seizure animals as shown by the darker, more intense 
band on the film (Fig. 5).  
 
Figure 6 shows p8GFAP expression at 24h and 72h post-insult in control, HI and HI-seizure 
animals in nine brain regions: frontal, parietal, temporal and occipital cortices, basal ganglia, 
thalamus, hippocampus, brain stem and cerebellum. At 24h post-insult, expression of p8GFAP was 
significantly upregulated in the four cortices in HI-seizure animals compared with controls. HI-
seizure animals had significantly increased p8GFAP expression in parietal, temporal and occipital 
 13 
cortices compared to HI animals. At 72h post-insult, p8GFAP expression was significantly 
upregulated in the four cortices, basal ganglia and thalamus, when compared with controls. HI-
seizure animals had significantly increased p8GFAP expression in frontal, temporal and occipital 
cortices and thalamus compared with HI animals. 
 
Expression of p13GFAP was not significantly different in any brain region studied at 24h post-
insult (Fig. 7). At 72h post-insult, p13GFAP expression was significantly upregulated in the four 
cortices and basal ganglia, when compared with controls. HI-seizure animals had significantly 
increased p13GFAP expression in the four cortices compared with HI animals. HI animals had 
significantly higher p13GFAP expression compared with controls in basal ganglia only (indicated 
by § in Fig. 7E). In the thalamus, there was a trend towards increased p13GFAP expression in HI-
seizure animals at 72h post-insult, but this was not significant across the three groups (p=0.058). 
Western blots for p8GFAP and p13GFAP were routinely stripped and re-probed with anti-GFAP 
antibody. GFAP expression was not significantly different across groups for any brain region at the 
time points examined (data not shown). 
 
pGFAP expression and brain injury 
HI triggers a cascade of events that ultimately result in brain damage. We examined which 
physiological variables had the greatest influence on pGFAP expression. Table 4 lists the Spearman 
correlation coefficients (rs) for the significant relationships identified. Animals that had increased 
pGFAP expression consistently had poor neurobehaviour and aEEG scores post-insult. At 72h post-
insult a strong association was identified between p13GFAP expression and aEEG score on day 1 
(Fig. 8A). Increased p13GFAP expression was also strongly associated with neurobehaviour score 
at 48hr (Fig. 8B). Similar relationships were found for p8GFAP. Animals with higher histological 
injury tended to have higher levels of pGFAP expression. A strong association was identified 
between cortical p13GFAP expression and the average cortical histology score (Fig. 8C). A similar 
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relationship existed between the cortical p8GFAP expression and the average cortical histology 
score at 72h post-insult (rs=0.600, p=0.002). The relationship between average cortical p8GFAP or 
p13GFAP expression and histology score (including non-cortical brain regions) was also significant 
(rs=0.491, p=0.017 for p8GFAP and rs=0.655, p=0.001 for p13GFAP). 
 
Discussion 
GFAP is a key cytoskeletal protein but little is known about its specific functions. Previous studies 
have created pGFAP antibodies, some of which are commercially available [40,41]. In this study, 
we generated and characterised our polyclonal antibodies against p8GFAP and p13GFAP to ensure 
that they detected only the phosphorylated form of GFAP, and that this phosphoprotein was 
detectable in astrocytes in the pig brain. Our results demonstrated that pGFAP expression was 
increased in brain regions that were vulnerable to HI brain damage and that increased pGFAP 
expression was associated with poor neurological outcomes and histological brain damage.  
 
GFAP can be phosphorylated at multiple sites and this influences the stability of the glial 
cytoskeleton, however there are very few studies examining the expression of pGFAP in the intact 
CNS. In vitro autoradiography studies have shown increased phosphorylation of GFAP in rat 
hippocampal slices following HI [42]. Two-dimensional immunoblotting identified an increase in 
pGFAP isoforms in brains from Alzheimer’s disease patients [43]. There is only one other study 
that has used a phospho-specific GFAP antibody to examine the expression of pGFAP in relation to 
a CNS disease, and those results support our observations. Using quantitative western blotting, 
Herskowitz et al. [44] detected an eight-fold increase in p13GFAP in post-mortem brains from 
individuals with frontotemporal lobe degeneration. 
 
Anatomy of cells expressing pGFAP 
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There are limited high magnification images detailing the anatomy of pGFAP-expressing 
astrocytes. We demonstrate that astrocytes expressing pGFAP have atypical cytoskeletal 
morphology, even in control brains. Our observations of pGFAP-expressing astrocytes with short 
processes are supported by previous literature [7]. It is likely that remodelling or ‘pruning’ is 
occurring our neonatal brains. In both human and rodents, GFAP expression increases with age 
[45]. Expression of pGFAP has been demonstrated in the adult human brain [44] but further study is 
required to determine whether GFAP phosphorylation changes with age.  
 
pGFAP expression in the HI brain 
We explored the relationships between antemortem variables, histological injury and expression of 
pGFAP. Although we could not identify a consistent physiological variable that drove 
phosphorylation of GFAP we consistently observed in that animals with increased p8GFAP in a 
particular region also had increased p13GFAP (72hr post-insult only). This increased pGFAP 
expression was associated with poor neurological outcome (aEEG or neurobehaviour score). The 
association between increased pGFAP expression and histological injury further confirms this 
relationship. Western blotting showed that increased phosphorylation of GFAP was restricted to 
regions of the brain that are damaged by an HI insult and pGFAP was not increased in areas that are 
relatively spared after HI. Our immunohistochemical images support this: In animals with mild or 
no histological damage (Fig. 4B), the expression of pGFAP was similar to control brains.  
 
Figure 9 indicates where phosphorylation of GFAP might play a role in the events following an HI 
insult. HI causes a series of initial events (grey boxes) such as decreased pH, ATP and glucose that 
ultimately result in cell death. Loss of glutamate transporters and seizures exacerbate extracellular 
accumulation of glutamate, which would contribute to increased cell death via excitotoxicity. This 
same rise in extracellular glutamate would also stimulate phosphorylation of GFAP, but it is unclear 
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whether this contributes to increased cell death or is potentially part of a long-term repair/plasticity 
process.  
 
Since there were no differences observed in the HI and HI-seizure animals in terms of the HI insult 
variables, it is likely that the development of seizures and increased pGFAP in some HI animals is 
due to other intrinsic or inter-individual factors. We hypothesized that pGFAP would be increased 
in HI animals due to the involvement of glutamate in the pathogenesis of HI brain injury. There 
were trends toward increased pGFAP expression in some brain regions of HI animals but this only 
reached significance for p13GFAP in basal ganglia at 72h post-insult (a three-fold increase 
compared with controls). However, when there is additional injury burden and potentially more 
glutamate release by post-HI seizures, there were large differences between control and HI-seizure 
animals. We observed a significant two- to three-fold increase in p8GFAP in the cortex at 24h post-
insult and a three- to seven-fold increase in p8GFAP and p13GFAP in various brain regions at 72h 
post-insult compared to controls. To further elucidate the role of seizures in GFAP phosphorylation, 
pGFAP expression could be examined without HI insult by using a standard kindling model or a 
status epilepticus model where spontaneous seizures are induced in rodents by electrical stimulation 
or chemical agents such as kainate or pilocarpine (for review, see [46]). 
 
Timing of increase in pGFAP 
GFAP protein expression as detected by western blot was not significantly different across groups 
for any brain region. Thus the observation of increased pGFAP was independent to the expression 
of regular GFAP. We have previously observed using immunohistochemistry that GFAP 
immunoreactivity is decreased in white matter and upregulated in grey matter after HI insults (see 
[28] Fig. 3A versus 3B). The increased grey matter and decreased white matter GFAP expression 
may effectively ‘cancel’ each other out in a cortical protein homogenate sample.  
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Phosphorylation of GFAP at Ser-8 but not Ser-13 was increased at 24h post-insult. At 72h post-
insult, the expression of p8GFAP and p13GFAP was similar, with areas such as cortex and basal 
ganglia showing increased pGFAP expression. This supports the concept of differential regulation 
of phosphorylation sites of GFAP.  Studies have shown that Ser-8 phosphorylation is regulated by 
PKA, PKC and cdc2 kinase, while Ser-13 phosphorylation is regulated by PKA, PKC, CaMKII, 
Rho kinase and CF kinase [47]. Increased phosphorylation at both Ser-8 and Ser-13 could be 
efficiently caused by increased activity of PKA or PKC but only an increase in cdc2 kinase activity 
would cause increased GFAP phosphorylation at Ser-8 independent of Ser-13. Alternatively, 
phosphorylation of GFAP at Ser-8 creates a conformational change that allows subsequent 
phosphorylation of Ser-13. As phosphorylation is a reversible process, we propose that modulation 
of kinase activity might represent an interesting therapeutic strategy for future research. 
 
Reactive gliosis and interactions with other proteins 
The increase in pGFAP expression could contribute to reactive gliosis by conferring plasticity to the 
astrocyte cytoskeleton. Geiger et al [48] have described two phases of glial activation in cerebral 
HIV infection but only increased immunoreactivity of GFAP and ezrin was associated with 
neuronal damage. Phosphorylation of GFAP may alter the interaction with ezrin and affect glial 
activation and/or neuronal cell damage. Studies have shown that Ser-8 phosphorylation of GFAP by 
PKC or cdc2 kinase enhances the interaction between GFAP and 14-3-3γ [49]. The converse is also 
plausible, that phosphorylation of GFAP disrupts its interactions with other proteins. Our previous 
studies in the rat and pig brain have shown the link between GFAP and GLAST (via NHERF1, 
ezrin and potentially other proteins) is important in HI brain injury: Regions of the brain exhibiting 
this co-association also showed no signs of cellular damage [25]. Future experiments could use 
immunoprecipitation to determine if phosphorylation of GFAP disrupts these protein interactions, 
thereby decreasing GLAST-mediated glutamate uptake and enhancing excitotoxic cell death.  
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Concluding remarks 
The role of GFAP phosphorylation in disease is relatively unexplored. We examined the 
phosphorylation of GFAP at Ser-8 and Ser-13 in control and HI neonatal pig brains. Previous 
literature [42-44] supports our finding of increased phosphorylation of GFAP, but further research 
is required to determine whether this is a beneficial or harmful change for the HI brain. 
Phosphorylation is an energy-dependent process, requiring adenosine triphosphate (ATP) 
conversion to adenosine diphosphate (ADP) by kinases to phosphorylate the serine or threonine 
residue. It seems counterproductive to utilise energy to phosphorylate a cytoskeletal protein in an 
energy-depleted physiological condition such as following HI. The alternative view is that 
phosphorylation of GFAP may be an essential part of a repair continuum: The astrocyte 
cytoskeleton is phosphorylated to depolymerise the cytoskeleton so that the astrocyte has increased 
plasticity and motility to promote survival of astrocytes (and the neurons they support) during the 
secondary energy failure phase of the disease. Given the vital role of astrocytes in the CNS, further 
studies of GFAP phosphorylation are required to understand its influence on the glial cytoskeleton 
in normal development and in diseases that affect the CNS. 
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Table 1: Histology scoring system 
 
Histological changes Grey Matter White Matter Area affected Grade 
None No abnormal features 0 0 
<10% 1 
10-25% 2 
25-50% 3 
Mild: Damage to 
individual cells 
Abnormal cell 
morphology, cell lysis, 
cell shrinkage, chromatin 
condensation 
Cell lysis, cell 
shrinkage 
>50% 4 
<25% 5 
25-50% 6 Moderate:  Damage in a layer or group of cells 
Vacuolation, chromatin 
condensation, cell lysis, 
cell death 
Vacuolation, 
poor 
myelination >50% 7 
<25% 8 
25-50% 9 Severe:  Damage to all cells within a certain area 
Features as per moderate 
damage but no evidence 
of any healthy cells 
Damage to 
myelinated 
tracts >50% 10 
 
 
 
Table 2: aEEG scoring system 
 
 Seizure activity 
Background EEG 
pattern 
No 
Seizures 
Epileptiform 
Activity 
Single 
Seizure 
Repetitive 
Seizures 
Status 
Epilepticus 
Continuous normal 
voltage (CNV) 0 0.5 1 1.5 N/A 
Discontinuous normal 
voltage (DNV) 1 1.5 2 2.5 3 
Burst suppression 
(BS) 2 2.5 3 3.5 4 
Continuous low 
voltage (CLV) 3 3.5 4 4.5 5 
Flat trace (FT) 4 4.5 5 5.5 N/A 
N/A: Not applicable as these physiological scenarios are unlikely to occur.   
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Table 3: Insult variables for the six groups in this study 
 
24h post-insult 72h post-insult Parameter Control HI HI Sz Control HI HI Sz 
Body weight 
(kg) 
1.52±0.07 1.61±0.05 1.64±0.13 1.85±0.15 1.6±0.08 1.52±0.07 
Insult length 
(min) 
0±0** 32.35±1.69 30.26±1.06 0±0^^ 29.41±0.88 31.43±1.70 
Time LaEEG 
(min) 0±0** 24.66±2.70 22.18±2.02 0±0^^ 23.25±1.18 25.75±2.22 
Time (min) 
MABP<70% 0±0** 10.65±2.11 11.58±2.51 0±0^^ 14.06±2.38 14.2±3.22 
Time (min) 
HR<140bpm 0±0 1.17±0.42 1.88±0.71 0±0 2.09±1.02 1.23±0.67 
pH end insult 
 7.48±0.02** 7.11±0.04 7.00±0.02 7.53±0.02^^ 7.09±0.02 7.06±0.03 
ABE end 
insult 6.00 ±0.83** -17.24±0.76 -18.23±1.57 8.52±1.79^^ -16.31±1.05 -17.36±1.20 
pCO2 end 
insult 40.83±1.73 37.1±4.93 49.93±3.67 38.12±1.48 43.43±3.83 43.91±2.80 
Data are mean ±SEM. **p<0.01 wrt 24h HI and HI Sz groups. ^^p<0.01 wrt 72h HI and HI Sz 
groups. LaEEG, low aEEG (<5µV). 
 
Table 4: Spearman correlation coefficients (rs) for the relationship between average cortical 
expression of p8GFAP and p13GFAP, histology and antemortem variables at 24h and 72h 
post-insult 
 
24h post-insult 72h post-insult 
Parameter examined Correlation with  
p8GFAP 
Correlation 
with 
p13GFAP 
Correlation 
with  
p8GFAP 
Correlation 
with 
p13GFAP 
Body weight n/s n/s n/s n/s 
Insult length n/s n/s n/s 0.462* 
Time LaEEG n/s n/s n/s 0.464* 
Time MABP <70% baseline n/s n/s n/s n/s 
Time HR<140bpm 0.552** n/s n/s n/s 
pH end insult -0.578** n/s n/s -0.568** 
ABE end insult -0.426* n/s n/s -0.608** 
pCO2 end insult n/s n/s n/s n/s 
Neurobehaviour score 8hr n/s -0.414* n/s n/s 
Neurobehaviour score 12hr n/s -0.421* n/s n/s 
Neurobehaviour score 16hr n/s -0.417* n/s n/s 
Neurobehaviour score 24hr -0.467* -0.422* -0.506* -0.628** 
Neurobehaviour score 48hr N/A N/A -0.634** -0.681*** 
Neurobehaviour score 72hr N/A N/A -0.432* -0.510* 
aEEG score 1hr 0.546** 0.585** n/s n/s 
aEEG score day 1 0.626** 0.525* 0.568** 0.530** 
aEEG score day 2 N/A N/A 0.503* 0.571** 
aEEG score day 3 N/A N/A 0.584** 0.612** 
N/A, data not available for this time point; n/s, not significant; * p<0.05; ** p<0.01; ***p<0.001. 
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Figure Legends 
Figure 1 
Western blotting using normal and pre-absorbed primary antibody solutions. A protein ~50kDa in 
size, representing pGFAP, was detected when the normal primary antibody solutions for p8GFAP 
(lane 1) and p13GFAP (lane 3) were used for immunoblotting, but the protein was not detected 
when pre-absorbed primary antibody solutions were used (lanes 2 and 4). Lane 5 shows 
representative no primary antibody control. 
 
Figure 2 
Western blotting with regular and dephosphorylated membrane shows specificity of 
phosphoantibody. Lane 1, untreated membrane; lane 2, dephosphorylated membrane; lane 3, no 
primary antibody control. pGFAP was detected on the untreated membrane (A, lane 1) but not on 
the dephosphorylated membrane (A, lane 2).  Blots were stripped and re-exposed to film to ensure 
antibodies were effectively removed (B). Immunoblotting for GFAP demonstrated that regular 
GFAP protein was detected on the untreated membrane (C, lane 1) and the dephosphorylated 
membrane (C, lane 2).  
 
Figure 3  
Immunohistochemistry for GFAP and pGFAP in pig brain. A-C: Individual astrocyte from control 
pig brain showing immunolabelling for p13GFAP (A), GFAP (B), and merged image (C). The 
p13GFAP antibody immunolabelled astrocytes that co-expressed GFAP protein. D: GFAP and 
pGFAP were differentially expressed in the astrocyte. Arrow indicates an astrocyte process 
expressing only GFAP (red); double-headed arrow indicates an astrocyte process co-expressing 
p13GFAP and GFAP (yellow); arrowhead indicates strong expression of p13GFAP in unusual 
terminal dilations of the astrocyte processes. E: Immunolabelling for pGFAP (green) was observed 
in end-feet of astrocytes contacting blood vessels (BV). Scale bars: A-D, 10µm; E, 50µm. 
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Figure 4 
Expression of pGFAP in control and HI pig brains. Expression of p13GFAP was observed in 
control brains (A) in atypical astrocytes with short processes (arrows) and in occasional astrocytes 
(double-headed arrow in A, and panel D) with longer processes that were atypical, that is, they had 
thickened, varicose processes. Expression of pGFAP in HI pig brains with mild or no damage at 
72h post-insult (B) was similar to control brains – pGFAP was observed in astrocytes with short 
processes (arrows). pGFAP expression was upregulated in HI animals with moderate to severe 
brain injury at 72h post-insult (C). In these animals, expression of pGFAP was associated with 
astrocytes with abnormal cytoskeletal morphology (E). a, astrocyte cell body; n, neuronal cell body. 
Scale bars A-C, 20µm; D-E, 10µm. 
 
Figure 5 
Example western blot for quantification studies. For illustrative purposes, 5µg of total protein from 
piglet parietal cortex was separated by SDS-PAGE and western blotting performed using the 
p8GFAP antibody. Lane 1, control pig; lane 2, HI pig; lane 3, HI-seizure pig (72h post-insult). 
pGFAP was detected in all pig brains and appeared strongly expressed in protein sample from the 
HI-seizure animal. 
 
Figure 6 
Expression of p8GFAP across nine brain regions from control, HI and HI-seizure pigs at 24h and 
72h post-insult. At 24h post-insult, p8GFAP expression was significantly different (Kruskal-Wallis 
test) between groups in the areas of frontal, parietal, temporal and occipital cortices. Post-hoc 
analysis (Mann-Whitney U test) determined that there were significant differences between control 
and HI-seizure animals (*, p<0.05; **, p<0.01) as well as significant differences between HI and 
HI-seizure animals (†, p<0.05; †† p<0.01). At 72h post-insult, p8GFAP expression was 
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significantly different between groups in the areas of frontal, parietal, temporal, occipital cortices, 
basal ganglia and thalamus. Post-hoc analysis determined that there were significant differences 
between control and HI-seizure animals (*, p<0.05; **, p<0.01) as well as significant differences 
between HI and HI-seizure animals (†, p<0.05; †† p<0.01). 
 
Figure 7 
Expression of p13GFAP across nine brain regions from control, HI and HI-seizure pigs at 24h and 
72h post-insult. At 24h post-insult, there were no significant differences between groups in any of 
the brain regions analysed. At 72h post-insult, p13GFAP expression was significantly different 
between groups in the areas of frontal, parietal, temporal, and occipital cortices and basal ganglia. 
Post-hoc analysis determined that there were significant differences between control and HI-seizure 
animals (*, p<0.05; **, p<0.01) as well as significant differences between HI and HI-seizure 
animals (†, p<0.05; †† p<0.01). In basal ganglia alone, there was significantly increased expression of 
p13GFAP in HI animals compared with control (§ p<0.05). 
 
Figure 8 
Relationship between increased pGFAP expression and brain injury. Increased p13GFAP 
expression at 72h post-insult was associated with poor aEEG score on day 1 (A), poor 
neurobehaviour score at 48h post-insult (B) and increased histological damage at 72hr post-insult 
(C). Individual data points, rs and p-values are shown. 
 
Figure 9 
Hypoxia-ischemia and phosphorylation of GFAP.  Grey boxes indicate initial events caused by HI 
that ultimately result in cell death. The post-HI increase in intracellular calcium and extracellular 
glutamate stimulate phosphorylation of GFAP, but it is unclear whether this contributes to increased 
cell death or is potentially part of a long-term repair/plasticity process. Phosphorylation of GFAP 
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causes destabilisation of the astrocyte cell process, changes in astrocyte structure and decreased 
regulation of the extracellular space. Phosphorylation of GFAP potentially disrupts the link between 
GFAP and the glutamate transporter GLAST (dotted line), which would contribute to excitotoxic 
cell death. 
 
 
 









